Citigroup’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.54M | Buy |
56,844
+49,159
| +640% | +$4.29M | ﹤0.01% | 2067 |
|
|
2026
Q1 | $645K | Sell |
7,685
-3,407
| -31% | -$197K | ﹤0.01% | 3391 |
|
|
2025
Q4 | $457K | Sell |
11,092
-57,387
| -84% | -$2.22M | ﹤0.01% | 3617 |
|
|
2025
Q3 | $2.69M | Buy |
68,479
+56,809
| +487% | +$1.45M | ﹤0.01% | 2420 |
|
|
2025
Q2 | $217K | Sell |
11,670
-23,150
| -66% | -$434K | ﹤0.01% | 4024 |
|
|
2025
Q1 | $632K | Buy |
34,820
+4,278
| +14% | +$94.3K | ﹤0.01% | 3549 |
|
|
2024
Q4 | $666K | Buy |
30,542
+13,148
| +76% | +$338K | ﹤0.01% | 3630 |
|
|
2024
Q3 | $476K | Buy |
17,394
+11,309
| +186% | +$315K | ﹤0.01% | 3761 |
|
|
2024
Q2 | $157K | Sell |
6,085
-16,651
| -73% | -$400K | ﹤0.01% | 4005 |
|
|
2024
Q1 | $682K | Buy |
22,736
+5,329
| +31% | +$116K | ﹤0.01% | 3331 |
|
|
2023
Q4 | $181K | Buy |
17,407
+13,539
| +350% | +$150K | ﹤0.01% | 3952 |
|
|
2023
Q3 | $52.9K | Buy |
+3,868
| New | +$48.7K | ﹤0.01% | 4113 |
|
|
2023
Q1 | – | Sell |
-46
| Closed | -$291 | – | 5583 |
|
|
2022
Q4 | $291 | Buy |
46
+2
| +5% | +$35 | ﹤0.01% | 5563 |
|
|
2022
Q3 | $1K | Sell |
44
-30
| -41% | -$821 | ﹤0.01% | 5621 |
|
|
2022
Q2 | $1K | Sell |
74
-74
| -50% | -$1.83K | ﹤0.01% | 6008 |
|
|
2022
Q1 | $7K | Sell |
148
-439
| -75% | -$24K | ﹤0.01% | 5679 |
|
|
2021
Q4 | $42K | Buy |
587
+186
| +46% | +$18.7K | ﹤0.01% | 5144 |
|
|
2021
Q3 | $47K | Buy |
401
+91
| +29% | +$10.6K | ﹤0.01% | 4762 |
|
|
2021
Q2 | $48K | Buy |
310
+89
| +40% | +$16.3K | ﹤0.01% | 4843 |
|
|
2021
Q1 | $42K | Sell |
221
-193
| -47% | -$32.5K | ﹤0.01% | 4793 |
|
|
2020
Q4 | $52K | Buy |
414
+97
| +31% | +$11K | ﹤0.01% | 6013 |
|
|
2020
Q3 | $34K | Buy |
317
+23
| +8% | +$2.73K | ﹤0.01% | 5843 |
|
|
2020
Q2 | $35K | Sell |
294
-282
| -49% | -$39.7K | ﹤0.01% | 6225 |
|
|
2020
Q1 | $58K | Buy |
576
+146
| +34% | +$27.1K | ﹤0.01% | 5843 |
|
|
2019
Q4 | $104K | Buy |
430
+307
| +250% | +$57.4K | ﹤0.01% | 5743 |
|
|
2019
Q3 | $20K | Sell |
123
-274
| -69% | -$52.1K | ﹤0.01% | 6733 |
|
|
2019
Q2 | $94K | Buy |
397
+127
| +47% | +$31.4K | ﹤0.01% | 5933 |
|
|
2019
Q1 | $71K | Buy |
270
+243
| +900% | +$41.9K | ﹤0.01% | 6053 |
|
|
2018
Q4 | $2K | Sell |
27
-44
| -62% | -$6K | ﹤0.01% | 7501 |
|
|
2018
Q3 | $14K | Buy |
+71
| New | +$14.9K | ﹤0.01% | 7235 |
|
Other funds holding DNTH
FFM
APM
OCA
Citigroup's DNTH Position: Q2 2026 in Review
Citigroup increased its Dianthus Therapeutics (DNTH) stake by 640% in Q2 2026, buying an estimated $4.29M and bringing the position to 56,844 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2067.
Citigroup first reported a position in DNTH in Q3 2018 and has held it in 30 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Citigroup held 56,844 shares of Dianthus Therapeutics worth $5.54M as of Q2 2026.
- Citigroup bought 49,159 Dianthus Therapeutics shares in Q2 2026, an estimated $4.29M.
- Dianthus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2067 holding.
- Citigroup first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 30 quarters since.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.